(Albany, US) , September 18, 2026 – DelveInsight’s “CAR-T Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the CAR-T Treatment Landscape @ https://www.delveinsight.com/report-store/car-t-pipeline-insight
Key Takeaways from the CAR-T Pipeline Report
DelveInsight’s CAR-T pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for CAR-T-based treatment.
The leading CAR-T Companies include Cartesian Therapeutics, Bristol-Myers Squibb, Cabaletta Bio, Fate Therapeutics, Allogene Therapeutics, CRISPR Therapeutics, Autolus Therapeutics, CARSGEN Therapeutics, Adicet Bio, Regeneron, and others.
Promising CAR-T Pipeline Therapies such as Descartes-08, Zola-cel, CABA-201, FT819, ALLO-501A, CTX112, CT1190B, AUTO-8, and others.
The companies which have their CAR-T drug candidates in the most advanced stage, i.e. Phase III, include Cartesian Therapeutics.
Gain in-depth knowledge of key CAR-T clinical trials, emerging drugs, and market opportunities @ CAR-T Clinical Trials Assessment
CAR-T Overview
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative personalized immunotherapy that genetically engineers a patient’s T cells to recognize and eliminate cancer cells with high specificity. Despite its remarkable clinical success, particularly in hematological malignancies, CAR-T therapy faces several challenges, including antigen heterogeneity, tumor immune evasion, treatment resistance, limited efficacy in solid tumors, and safety concerns such as cytokine release syndrome (CRS). Ongoing advances in target selection, CAR design, dosing strategies, and combination approaches aim to overcome these limitations and improve therapeutic outcomes, positioning CAR-T therapy for an increasingly important role in precision oncology.
CAR-T cells are genetically engineered T lymphocytes designed to recognize and eliminate cancer cells through the expression of a synthetic chimeric antigen receptor consisting of an extracellular antigen-binding domain — typically a single-chain variable fragment (scFv) — that recognizes tumor-associated antigens, and an intracellular signaling domain that activates T-cell proliferation, persistence, and cytotoxicity. Co-stimulatory molecules such as CD28, 4-1BB, and OX40 further enhance CAR-T cell function and antitumor activity, and CAR constructs have evolved from first-generation receptors with only a CD3ζ signaling domain to advanced second-, third-, and fourth-generation designs that incorporate additional co-stimulatory domains and cytokine-secreting modules to improve efficacy, durability, and immune activation.
Therapeutic efficacy largely depends on selecting an appropriate target antigen that is highly expressed on tumor cells while showing minimal expression on healthy tissue; once activated, CAR-T cells eliminate cancer cells by releasing cytotoxic molecules, secreting pro-inflammatory cytokines, and recruiting other immune cells such as natural killer cells and macrophages. However, CAR-T therapy carries safety concerns including CRS, neurotoxicity, prolonged cytopenias, immunosuppression, infections, and on-target off-tumor effects, and its efficacy is further challenged by tumor antigen heterogeneity, antigen loss, immune escape, and the immunosuppressive tumor microenvironment — particularly in solid tumors. Next-generation strategies under development include multi-antigen targeting, switchable activation systems, optimized co-stimulatory domains, controllable CAR-T systems, gene-editing technologies, and alternative platforms such as CAR-NK cells, all aimed at broadening the clinical utility of CAR-based therapies.
The first CAR-T cell therapy approved by the U.S. FDA was tisagenlecleucel in 2017, initially for pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, with later approvals for certain relapsed or refractory large B-cell lymphomas; axicabtagene ciloleucel followed that same year for adults with relapsed or refractory large B-cell lymphomas after multiple lines of systemic therapy. Since these landmark approvals, CAR-T cell therapy has become an established treatment option for several hematologic malignancies, while ongoing trials continue to explore its potential across cancers such as multiple myeloma, central nervous system tumors, hepatocellular carcinoma, and lung cancer, as well as a growing range of autoimmune diseases.
CAR-T Emerging Drugs Profile
Descartes-08: Cartesian Therapeutics Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA), using a novel modality to treat generalized myasthenia gravis (gMG) and other autoimmune diseases. Unlike anti-B-cell agents, which do not address long-lived plasma cells, or FcRn blockers and complement inhibitors, which intervene only after autoantibodies are produced, Descartes-08 is designed to halt autoantibody production by targeting pathogenic long-lived plasma cells that can survive for decades in the body. Currently, the drug is in the Phase III stage of development for the treatment of gMG.
Zola-cel: Bristol-Myers Squibb Zola-cel (zolacabtagene autoleucel) is an investigational autologous CD19-directed CAR-T cell therapy being developed for severe autoimmune diseases rather than cancer, designed to selectively eliminate CD19-positive B cells that drive autoantibody production with the goal of achieving an “immune reset” after a single infusion. Early studies have shown encouraging efficacy and a manageable safety profile, and Bristol Myers Squibb is evaluating zola-cel across indications including systemic lupus erythematosus, systemic sclerosis, multiple sclerosis, myasthenia gravis, and idiopathic inflammatory myopathies. Currently, the drug is in the Phase III stage of development for the treatment of systemic scleroderma.
CABA-201: Cabaletta Bio CABA-201 is an investigational autologous CD19-directed CAR-T cell therapy for B cell-mediated autoimmune diseases, incorporating a fully human CD19-binding domain and a 4-1BB co-stimulatory domain for deep but transient B-cell depletion after a single infusion, aiming for an “immune system reset” and durable, drug-free remission without chronic immunosuppression. It is being evaluated in the RESET™ program across indications including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies, generalized myasthenia gravis, and pemphigus vulgaris. Currently, the drug is in the Phase II/III stage of development for idiopathic inflammatory myopathy or juvenile idiopathic inflammatory myopathy.
FT819: Fate Therapeutics FT819 is an investigational off-the-shelf, induced pluripotent stem cell (iPSC)-derived CD19-targeted CAR-T cell therapy manufactured from a clonal iPSC master cell bank, enabling standardized treatment without patient-specific manufacturing. Its 1XX CAR targeting CD19 is designed to provide potent, sustained B-cell depletion with improved safety and T-cell persistence, and it is being evaluated for systemic lupus erythematosus, lupus nephritis, systemic sclerosis, ANCA-associated vasculitis, and idiopathic inflammatory myopathies. Currently, Phase II — its highest stage of development — is underway for systemic lupus erythematosus and lupus nephritis.
ALLO-501A: Allogene Therapeutics ALLO-501A is an investigational allogeneic, off-the-shelf CD19-targeted CAR-T cell therapy for relapsed or refractory large B-cell lymphoma (LBCL), with clinical studies demonstrating encouraging efficacy, durable responses, and a manageable safety profile as a readily available alternative to autologous CAR-T. Currently, the drug is in the Phase II stage of development for diffuse large B-cell lymphoma.
CTX112: CRISPR Therapeutics CTX112 is an investigational allogeneic, off-the-shelf CD19-targeted CAR-T cell therapy for B-cell malignancies, manufactured from healthy donor T cells using CRISPR/Cas9 gene-editing technology to enhance persistence, improve antitumor activity, and reduce graft-versus-host disease risk. It is being evaluated for relapsed or refractory B-cell non-Hodgkin lymphoma and CLL/SLL. Currently, the drug is in the Phase I/II stage of development for relapsed/refractory hematologic autoimmune disease.
CT1190B: CARSGEN Therapeutics CT1190B is an investigational autologous CD19-targeted CAR-T cell therapy for B-cell malignancies, particularly relapsed or refractory B-cell non-Hodgkin lymphoma, engineered to selectively eliminate CD19-positive malignant B cells. Early studies show promising antitumor activity and a manageable safety profile. Currently, the drug is in the Phase I stage of development for systemic lupus erythematosus.
AUTO-8: Autolus Therapeutics AUTO-8 is an investigational dual-targeted autologous CAR-T cell therapy for relapsed or refractory multiple myeloma, combining an optimized BCMA-targeting CAR with Autolus’ fast off-rate CD19 CAR (obe-cel) to enhance tumor cell killing, improve durability, and reduce antigen escape. AUTO-8 is currently in a Phase I clinical trial, with early results showing encouraging clinical activity, durable responses, and a favorable safety profile.
The CAR-T Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for CAR-T-based treatment, with aggregate therapies developed by each company.
It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for CAR-T treatment.
CAR-T Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
CAR-T drugs under development are categorized based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and funding for future advancement of the CAR-T market.
Uncover critical updates on therapeutic innovations and their potential impact on patients @ CAR-T Unmet Needs
CAR-T Companies
Cartesian Therapeutics, Bristol-Myers Squibb, Cabaletta Bio, Fate Therapeutics, Allogene Therapeutics, CRISPR Therapeutics, Autolus Therapeutics, CARSGEN Therapeutics, Adicet Bio, Regeneron, Miltenyi Biomedicine, TriArm Therapeutics (Taiwan) Limited, PeproMene Bio, Inc., Hebei Senlang Biotechnology Inc., Ltd., Allotera Therapeutics, Takara Bio, Immunotech Biopharma, Chongqing Precision Biotech Co., Ltd, Elicera, Tempest Therapeutics, Eutelix, Precigen, Inc, Mustang Bio, BioNTech, Sana Biotechnology, Immix Biopharma, Kyverna Therapeutics, TC BioPharm, and others.
CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
Oral
Intravenous
Subcutaneous
Parenteral
Topical
CAR-T Products have been categorized under various Molecule types such as:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the CAR-T Pipeline! @ CAR-T Market Drivers and Barriers, and Future Perspectives
Scope of the CAR-T Pipeline Report
Coverage- Global
CAR-T Companies- Cartesian Therapeutics, Bristol-Myers Squibb, Cabaletta Bio, Fate Therapeutics, Allogene Therapeutics, CRISPR Therapeutics, Autolus Therapeutics, CARSGEN Therapeutics, Adicet Bio, Regeneron and others.
CAR-T Pipeline Therapies- Descartes-08, Zola-cel, CABA-201, FT819, ALLO-501A, ALLO-329, CTX112, AUTO-8, CT1190B, Prulacabtagene leucel, MB-CART19.1, ARM011, BAFFR-CAR T cells, S1904 CD19 CAR-T, WU-CART-007, TBI-1501, CAR-T-19 cell injection, MC-1-50, ELC-301, ELC-401, PMB-101, PMB-102, TPST-4003, TPST-2003, EU301, EU307, PRGN-3006, PRGN-3005, PRGN-3007, MB-101, BNT211, SG293, NXC-201, KYV-102, Sofi-cel, TCB-003 and others.
CAR-T Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
CAR-T Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full CAR-T Pipeline Analysis Today! @ CAR-T Drugs and Companies
Table of Contents
Introduction
Executive Summary
CAR-T: Overview
Pipeline Therapeutics
Comparative Analysis
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
Inactive Products
CAR-T Key Companies
CAR-T Key Products
CAR-T Unmet Needs
CAR-T Market Drivers and Barriers
CAR-T Future Perspectives and Conclusion
CAR-T Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/car-t-pipeline-insight
